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Abstract
Background: Polyunsaturated fatty acids (PUFAs) such as g-linolenic acid (GLA), arachidonic acid (AA) and
docosahexaenoic acid (DHA) have cytotoxic action on glioma cells.
Results: We evaluated the cytotoxic action of GLA, AA and DHA on glioma cells with specific reference to the
expression of miRNAs. Relative expression of miRNAs were assessed by using high throughput nanocapillary real-
time PCR. Most of the miRNA target genes that showed altered expression could be classified as apoptotic genes
and were up-regulated by PUFA or temozolomide treatment, while similar treatments resulted in repression of the
corresponding mRNAs, such as cox2, irs1, irs2, ccnd1, itgb3, bcl2, sirt1, tp53inp1 and k-ras.
Conclusions: Our results highlight involvement of miRNAs in the induction of apoptosis in glioma cells by fatty
acids and temozolomide.
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Background
Malignant gliomas are among the most devastating of can-
cers and are a major cause of mortality in a young popula-
tion with a median survival time of 9 months following
cytoreductive surgery, radiotherapy and chemotherapy.
Despite advances in surgery, chemotherapy, and radiother-
apy, the prognosis of patients with this fatal disease has
not improved significantly over the past 20 years [1,2].
Our previous studies showed that certain polyunsaturated
fatty acids, especially g-linolenic acid (GLA), arachidonic
acid (AA), eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA) have tumoricidal action against glioma
cells both in vitro and in vivo [3-7]. Understanding how
the signaling pathways involved in surviving and inducing
cell death of different glioma cells are regulated during
PUFA treatment is important for the development of
more effective tumor therapies including PUFAs alone or
in combination with other drugs [8]. Several research
groups have analyzed the mRNA expression profile of
different cancer types to reveal novel gene markers for
diagnosis and theraphy and to better understand the regu-
latory pathways and genetic networks [9,10].
The mechanisms of action that are involved in the
effects of PUFAs on cell regulation are complex. Thus, the
use of microarrays, which allows the detection of differen-
tially regulated mRNAs of thousands of different genes
simultaneously, is a useful tool to elucidate such complex
systems. To date, several studies have used microarrays to
study the effects of PUFAs on cell regulation, including
their effects on brain function [9,10] and cancer [11,12],
but only limited data is available as to how PUFAs can
modulate the expression of microRNAs [12]. It is now
possible to analyze portions of the miRNAome using
microarray or high throughput polymerase chain reaction
(PCR) methodologies [13,14]. But, to date, no data is avail-
able as to the effect of different PUFAs on miRNA expres-
sion in glioblastoma cells.
MicroRNAs are small non-coding RNA molecules that
are currently being recognized as endogenous physiologi-
cal regulators of gene expression. These small RNAs are
capable of controlling gene expression by repression of
translation/transcription (“RNA interference”) [15,16].
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signatures, several microRNAs are deregulated in several
different tumor entities, suggesting their involvement in
the basic processes of tumorigenesis. MicroRNAs may
act as oncogenes by inhibiting translation of tumor sup-
pressor mRNAs, but they can act as tumor suppressor
genes as well, by inhibiting
translation of oncogenic mRNAs [16-18]. MicroRNAs
may also interfere with other characteristics of the malig-
nant phenotype, including chemoresistancy, angiogenesis,
invasion, metastasis or immunogenicity [18-20]. However,
how miRNAs affect the drug sensitivity of cancer cells is
still unknown. Here we report miRNA profiling study of
three different glioma cells treated with three different
PUFAs (GLA, AA and DHA) and temozolomide as a che-
motherapeutic agent currently used in glioma treatment.
Materials and methods
Treatment and cultivation of glioblastoma cell lines
Glioblastoma cells (U373, GBM2, GBM5) were grown at
37°C under 5% of CO2 and 100% humidity in DMEM and
RPMI medium supplemented with 10% FCS (Sigma-
Aldrich), and penicillin-streptomycin antibiotics. The cells
were treated with 50 and 100 μM AA, DHA, TMZ, 75 and
150 μM GLA for 24 hours and then harvested with trypsin
and washed with PBS.
Purification of microRNA from glioblastoma cells
Purification of microRNA was done with the High Pure
miRNA Isolation Kit (Roche, Cat. no. 05080576001) as
described previously with slight modifications [21]. Briefly:
after harvesting, glioblastoma cells (5 × 10
6) were washed
with PBS, collected by centrifugation and lyzed with
400 μl 20% Binding Buffer. 320 μl Binding Enhancer
(Roche) was added, mixed and loaded onto the filter col-
umns (Roche). Next the filters were washed in two steps
with 500 and 300 μl of Washing Buffer (Roche), then the
RNA was eluted by adding 100 μl Elution Buffer (Roche).
All other steps were done according to the manufacturer’s
recommendations. The quality and quantity was assessed
spectrophotometrically (Nanodrop, USA) and with 2100
Bioanalyzer (Agilent).
Profiling of microRNAs by high-throughput, nanocapillary
QRT-PCR
Amplification of the samples was followed in real time
with an OpenArray NT Cycler (BioTrove Inc., Woburn,
MA, now Life Technologies, Applied Biosystems). An ali-
quot of each Taqman miRNA assay was sent to BioTrove
(Woburn, MA) for loading in their OpenArray plates.
Taqman assays are loaded by BioTrove in a customer-spe-
cified layout. A third fluorescent dye (ROX), present in the
Taqman assay mixture, was imaged to provide quality
assessment of manufacturing and loading of the arrays.
cDNA samples (or water for no template controls) were
added to a 384-well plate containing universal Taqman
master mix (Applied BioSystems, P/N 4324018) for Open-
Array amplification. The OpenArray autoloader transfers
the cDNA/master mix from the plate to the array
through-holes by capillary action. Each subarray was
loaded with 5.0 μl of master mix containing 1.2 μlo f
reverse transcribed miRNA. The array is manually trans-
ferred to the OpenArray slide case and sealed. The plates
were cycled in the OpenArrayNT cycler (up to three
arrays simultaneously) under the following conditions:
50°C for 15 seconds, 91°C for 10 minutes, followed by 50
cycles of 54°C for 170 seconds and 92°C for 45 seconds.
T h eB i o t r o v eO p e n A r r a y N TC y c l e rS y s t e ms o f t w a r e
(version 1.0.2) uses a proprietary calling algorithm that
estimates the quality of each individual threshold cycle
(CT) value by calculating a CT confidence value for the
amplification reaction. In our assay, CT values with CT
confidence values below 300 (average CT confidence of
the non-target amplification reactions plus 3 standard
deviations) were considered background signals. Higher
CT confidence levels were considered positive and were
analyzed further. Normalization was performed by using
median expression of all miRNAs analyzed in the study
for each sample.
Determination of mRNA levels by using QRT-PCR
Total RNA was used for QRT-PCR analysis as described
earlier [22]. Briefly, 2 μg of total RNA from each sample
were reverse transcribed in the presence of random pri-
mers in a total volume of 20 μl. After dilution with 20 μl
of water, 1 μl of the diluted reaction mix was used as tem-
plate in QRT-PCR. The 20 μl reaction volume contained
0.2 mM of dNTP, 1× PCR reaction buffer (ABGene,
Epsom, UK), 6 mM of each primer, 4 mM of MgCl2,1 ×
SYBR Green I (Molecular Probes, Eugene, OR) at final
concentration, and 0.5 U of thermostart Taq DNA poly-
merase (ABGene). Amplification was carried out with the
following cycling parameters: 600 s heat start at 95°C,
45 cycles of denaturation at 95°C for 25 s, annealing at
60°C for 25 s, and fluorescence detection at 72°C for 15 s.
A total of 45 cycles were run. All the PCRs were per-
formed in triplicate. After amplification, a melting curve
was created to verify the specificity of the PCR reactions.
Relative expression ratios were normalized to GAPDH
and HPRT, as widely used housekeeping genes [22]. The
PCR primers used in this study are listed in Table S1 (see
Additional file 1, Table S1).
Confirmation of HTS QRT-PCR miRNA expression data by
traditional QRT-PCR
The reverse transcription reaction was performed with
the TaqMan
® MicroRNA Reverse Transcription Kit
(Applied Biosystems, United States, California). 350 ng
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t h ep r e s e n c eo f5 ×R TT a q M a n
® MicroRNA Assays
(Applied Biosystems). 8 μl reaction mixture contained
0.2 μld N T P s ,1 . 5 0μlM u l t i S c r i b e ™ Reverse Transcrip-
tase (50 U/μL), 0.8 μl 10× RT Buffer, 0.9 μlM g C l 2 ,
0.1 μlR N a s eI n h i b i t o r( 2 0U / μL), 1.5 μl5 ×R Tp r i m e r
and the template in a total volume of 3 μl. Reverse
Transcription was carried out with the following cycling
parameters in a thermocycler (Bioneer, Daedong,
Korea): 16°C for 2 minutes, 42°C for 1 minutes, 50°C for
1 second, 45 cycles, then hold the samples on 85°C for
5 minutes. After dilution with 64 μl of water, 9 μlo ft h e
diluted reaction mix was used as template in QRT-PCR.
QRT-PCR was performed on the Excicycler instru-
ment (Bioneer) with the TaqMan protocol. 20 μlP C R
mixture contained 10 μlT a q M a n
® Universal PCR Mas-
ter Mix (Applied Biosystems), 1 μlo ft h eT a q M a n
®
MicroRNA Assays and 9 μl of the diluted cDNA.
Results
MicroRNA profiling of PUFA treated glioblastoma cells
We have analyzed the expression of 112 microRNA by
using high-throughput, nanocapillary QRT-PCR (HTS
QRT-PCR) (OpenArray system formerly Biotrove, now
Applied Biosystems, Life Technologies) in three different
human glioblastoma cell lines (U373, GBM3 and GBM5)
in triplicates in response to different PUFAs. In this study,
we investigated the effects of GLA, DHA and AA that are
PUFAs. In order to differentiate specific responses to dif-
ferent PUFAs we analyzed the effect of temozolomide,
which is an oral alkylating agent that is used for the treat-
ment of brain tumors [23]. We used temozolomide to
identify miRNA expression changes that are due to apopto-
sis and to see whether there are differences or similarities
between the changes caused by PUFAs and temozolomide.
By using nanocapillary QRT-PCR, we generated raw
expression data of treated and un-treated control glioblas-
toma cells. Relative changes in miRNA expression was cal-
culated. Of the 112 miRNAs analyzed, 65 gave significant
signals (below Ct value of 26, upon which this technology
results in weaker reproducibility with high standard devia-
tion of the repeated runs). 19 miRNAs were selected based
on their selective expression changes related to cell lines
or PUFA treatment (Table 1). The results for all the ana-
lyzed miRNAs are shown in Table S2 where each block
represent the relative and average expression of miRNAs
of each glioblastoma cells (see Additional file 2, Table S2).
Based on the results obtained, we could conclude that
there are specific expression changes in the miRNA levels
of PUFA treated cells. Mosto ft h em i R N Ae x p r e s s i o n
changes can be dedicated to the general apoptotic cell
death (with all PUFAs as well as temozolomide), such as
m i r - 3 4 ,m i r - 2 5 ,m i r - 1 7 ,m i r - 2 6 a ,m i r - 2 9 c ,m i r - 3 1 ,m i r -
200a, mir-206 in the three cell lines tested. The same gen-
eral effect, up-regulation of mir-140, mir-323 and mir-
133b could be seen but only in U373 cells, but not in
GBM2 nor in GBM5 cells (Table 1). Besides non-specific
modification of miRNA expression, we could detect temo-
zolomide and PUFA treatment-specific alterations in
miRNA level. In case of temozolomide we found specific
up-regulation of mir-182, and down-regulation of mir-16
and mir-183. Mir-143 was found to be repressed and mir-
20b was induced by PUFA treatments (Table 1).
The expression of mir-125b was repressed in GBM5
cells only, while, mir-197 was up-regulated in U373
cells. The same cell-type specificity could be observed in
the case of mir-206 that was down-regulated in GBM2
cells, but was up-regulated in U373 cells. These differ-
ences in the expression of certain types of miRNAs in
response to various PUFAs by different glioma cells
could be due to differences in the signalling pathways in
different types of tumor cell lines, even though the three
studied cell lines were glioblastoma cells.
Validation of HTS QRT-PCR data by traditional QRT-PCR
However, several studies have already validated relative
gene expression data obtained by HTS QRT-PCR
miRNA profiling with this technology (24). Therefore, we
selected six key miRNAs and determined their relative
expression ratios in samples treated with different PUFAs
and temozolonide relative to untreated samples in all the
three glioma cells. miRNA expression was determined by
using Taqman probes (Applied Biosystems, Life Technol-
ogies) in both methods used. Data obtained by both HTS
QRT-PCR and traditional QRT-PCR resulted in very
consistent data, 75% of the data showed similar changes
to each other and we obtained only 4% more data with
the traditional QRT-PCR. Details of the confirmatory
data can be found in Table 2.
3.3 Validation of mRNA expression of selected
miRNA target genes
Most of the targets of the differentially expressed miRNAs
in response to PUFA treatment were apoptotic genes
(Table 3). It is likely that the exhibited changes in miRNAs
are as a consequence of apoptosis. This is supported by the
fact that most of the mRNAs that are altered in response
to PUFAs and temozolomide as noted in the present study
are regulated by 11 miRNAs that can be classified as apop-
tosis-specific genes. Furthermore, most of the genes are
overlapping (i.e. are targets for more than one miRNA),
suggesting the existence of parallel regulatory pathways.
These genes are the following: TP53INP1, MAP3K5,
PDCD4, SIRT1, APP, BBC3, TNFRSF21, SGMS1.
To further validate our hypothesis we selected six
miRNAs (mir-16, mir-20b, mir-22, mir-30c, mir-143 and
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Page 3 of 8Table 1 Results of 19 selected miRNA expression in glioma cells (G2, GBM2; G5, GBM5; U3, U373) in response to different PUFA (A100, A50, arachidonic acid
at 100 and 50 μM concentrations, respectively; D100, D50, DHA at 100 and 50 μM concentrations, respectively; G100, G50, GLA at 100 and 50 μM
concentrations, respectively) or temozolomide (T100, 100 μM temozolomide) treatment
ASSAY G2
A100
G2
A50
G2
D100
G2
D50
G2
G100
G2
G50
G2
T100
G5
A100
G5
A50
G5
D100
G5
D50
G5
G100
G5
G50
G5
T100
U3
A100
U3
A50
U3
D100
U3
D50
U3
G100
U3
G50
U3
T100
hsa-miR-
29a
3,20 4,86 5,43 4,61 n.d. n.d. -5,47 -3,88 -3,86 -4,82 -3,19 n.d. n.d. -4,27 -2,50 -4,70 n.d. 2,58 -6,85 n.d. -10,13
hsa-miR-
16
-0,29 0,51 -0,78 0,22 n.d. n.d. -3,78 3,66 2,13 n.d. n.d. 0,15 -0,22 -3,89 -2,11 -1,80 -1,50 -1,61 -1,83 0,34 -5,82
hsa-miR-
22
0,01 -0,16 0,57 -0,95 -3,54 -2,27 -3,39 -1,33 0,09 -0,93 0,15 n.d. n.d. -3,33 n.d. n.d. -0,01 0,13 -0,15 0,22 -1,87
hsa-miR-
20b
3,58 3,25 -0,41 0,40 n.d. n.d. -2,47 -0,56 0,26 -0,04 0,49 -3,25 -1,06 -3,06 0,68 0,73 1,63 2,71 -0,05 0,09 -0,50
hsa-miR-
29c
0,85 0,89 -4,50 -2,03 -1,75 -2,06 -2,41 -4,51 -3,90 -4,48 -1,90 4,07 n.d. -2,40 1,50 -0,33 -0,38 0,55 3,59 3,00 -0,09
hsa-miR-
30c
-2,79 -2,92 -4,09 -4,93 -2,48 -2,07 -2,11 n.d. n.d. n.d. n.d. 0,03 -0,37 -1,69 -2,64 0,43 n.d. 5,99 0,36 -0,79 -0,07
hsa-miR-
17
-1,29 -1,08 -0,87 -0,78 -1,34 -0,29 -1,28 0,01 0,72 0,80 0,58 -4,07 -4,96 -1,30 n.d. 1,08 n.d. n.d. n.d. 2,15 -0,06
hsa-miR-
25
-2,62 -1,15 -4,06 -1,40 -2,00 -1,22 -1,27 n.d. n.d. 3,50 3,43 -0,75 n.d. -1,13 0,73 -0,01 2,62 4,19 -0,94 0,20 0,06
hsa-miR-
206
0,39 -0,49 -2,29 -0,29 -3,46 -2,37 -1,22 n.d. n.d. n.d. n.d. 1,10 0,08 -0,93 -2,52 -2,23 -1,22 -0,71 0,46 0,36 0,08
hsa-miR-
183
0,32 -0,84 0,60 0,80 n.d. 4,02 -1,09 n.d. n.d. 1,38 0,47 0,24 0,69 -0,79 1,37 0,55 1,80 0,90 2,18 1,47 0,40
hsa-miR-
224
0,27 0,24 -0,92 -0,32 -1,47 -2,41 -0,97 n.d. -0,14 -2,36 -1,82 -3,83 -1,45 -0,37 0,61 0,14 2,57 2,43 0,59 1,60 0,53
hsa-miR-
145
-5,70 -4,30 -7,35 -2,37 -2,72 0,26 -0,77 -1,76 -1,50 -1,19 -1,33 -1,78 -1,87 -0,14 0,89 0,73 0,65 0,37 0,95 0,97 1,36
hsa-miR-
26a
-0,87 -0,09 -0,77 -0,27 -0,36 0,32 -0,57 -1,09 -1,17 -1,86 -0,66 -2,07 -1,01 -0,08 5,66 5,63 1,69 -0,42 3,17 n.d. 2,85
hsa-miR-
181a
n.d. n.d. n.d. n.d. 1,83 0,75 -0,55 3,51 3,96 3,59 4,30 -0,84 0,28 -0,01 n.d. 2,42 -2,86 0,73 0,75 -0,08 4,01
hsa-miR-
208
-1,97 -0,79 0,21 -0,55 -1,29 -2,44 -0,46 4,11 3,85 1,18 1,28 -0,64 0,53 0,86 n.d. n.d. n.d. n.d. n.d. n.d. n.d.
hsa-miR-
143
-1,28 0,33 -1,52 -0,90 0,25 n.d. -0,37 -3,84 -3,82 -2,15 -1,19 1,51 0,06 1,61 n.d. n.d. n.d. n.d. n.d. n.d. n.d.
hsa-miR-
20a
0,76 0,59 -0,62 -0,33 -1,90 -1,60 -0,32 n.d. n.d. n.d. n.d. 2,25 1,41 2,20 n.d. n.d. n.d. n.d. n.d. n.d. n.d.
hsa-miR-
149
0,47 -0,40 -0,06 -0,01 -0,87 -0,60 1,20 0,93 0,08 3,19 0,74 3,80 2,63 4,82 n.d. n.d. n.d. n.d. n.d. n.d. n.d.
hsa-miR-
125b
0,73 -0,01 0,31 0,67 n.d. n.d. n.d. -2,19 -2,82 -2,35 -1,35 0,01 -0,92 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
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8mir-145) from the differentially expressed miRNAs and
nine genes which are targets of the selected miRNAs.
All the target genes code for proteins that have major
role in triggering apoptosis in cancer cells. mRNA levels
of target genes were determined by using gene-specific
primers and traditional QRT-PCR. Total RNA was
extracted from the same treated and control cells that
was used for miRNA profling The expression of these
mRNA coding genes were calculated (treated vs. un-
treated) and the results are shown in Figure 1. It is evi-
dent that there is an inverse correlation between
miRNA expression and mRNA expression changes as
expected. In case of bcl-2 and sirt-1 this inverse correla-
tion could be seen in 6 out of 7 cases when miRNA
expression changes were recorded. Similar high correla-
tion could be detected in case of itgb3, k-ras, irs1, irs2,
cox2 and ccnd1 genes.
Discussion
Understanding how the signaling pathways involved in
surviving and inducing cell death of different glioma cells
are regulated during PUFA treatment is important for
the development of more effective tumor therapies
including PUFAs alone or in combination with other
drugs. In the present study, we focued on microRNA
expression changes, as microRNAs are currently being
recognized to have central role in the regulation of the
expression of key gene families that are involved in cell
physiology and the fate of cancer cells.
We have analyzed the expression of 112 microRNA by
using the OpenArray™ nanocapillary HTS QRT-PCR
technology (Applied Biosystems). This method merges
the high-throughput of DNA-microarrays with the
sound characteristics of QRT-PCR, therefore ideal for
screening the expression of hundreds of genes from
Table 2 Correlation of relative miRNA expression obtained from HTS QRT-PCR or traditional QRT-PCR
miRNA-16 A D G T miRNA-30c A D G T
GBM2 HTS QRT-PCR -0,2 -0,78 n.d. -3,78 GBM2 HTS QRT-PCR -2,78 -4,08 -2,4 -2,1
QRT-PCR -1,02 -1,02 -0,5 -1,59 QRT-PCR -5,63 -1,86 -2,16 -1,44
confirm n y y confirm y y y y
GBM5 HTS QRT-PCR n.d. 3,49 -0,75 -1,13 GBM5 HTS QRT-PCR -3,88 -4,8 n.d. -4,26
QRT-PCR 0,1 0,87 -0,92 -3,32 QRT-PCR -5,84 -2,71 -2,69 -2,72
confirm y y y confirm y y y
U373 HTS QRT-PCR n.d. -0,02 -0,15 -3,78 U373 HTS QRT-PCR -2,49 n.d. -6,84 -10,13
QRT-PCR -1,25 -1,35 -1,66 -1,2 QRT-PCR -4,88 -3,17 -4,78 -3,74
confirm n n y confirm y y y
miRNA-20b A D G T miRNA-143 A D G T
GBM2 HTS QRT-PCR 3,58 -0,4 n.d. -2,47 GBM2 HTS QRT-PCR -1,2 -1,5 2,61 -0,36
QRT-PCR 1,18 -1,02 -0,11 -2,07 QRT-PCR -1,3 -5,38 -3,8 -2,44
confirm y y y confirm y y n n
GBM5 HTS QRT-PCR 4,11 1,17 -0,6 0,85 GBM5 HTS QRT-PCR -1,76 -1,18 -1,77 -0,14
QRT-PCR 3,81 4,34 4,02 2,31 QRT-PCR -3,8 -3 -3,62 -1,53
confirm y y n y confirm y y y n
U373 HTS QRT-PCR 0,72 2,62 -0,93 0,05 U373 HTS QRT-PCR 0,67 1,62 -0,04 -0,5
QRT-PCR 2,37 1,18 0,41 0,63 QRT-PCR -1,98 0,05 1,25 -1,45
confirm y y n y confirm n n n y
miRNA-22 A D G T miRNA-145 A D G T
GBM2 HTS QRT-PCR 0,01 0,57 -3,53 -3,38 GBM2 HTS QRT-PCR -5,7 -7,35 -2,72 -0,77
QRT-PCR -1,85 -0,87 -6,26 -2,16 QRT-PCR -8,5 -1,5 -1,45 -1,64
confirm n n y y confirm y y y y
GBM5 HTS QRT-PCR -1,08 -186 -2,07 -0,08 GBM5 HTS QRT-PCR -2,19 -2,35 0,01 n.d.
QRT-PCR -2,15 -2,69 -3,18 -2,06 QRT-PCR -4,75 -4,74 -2,1 -20,71
confirm y y y n confirm y y n
U373 HTS QRT-PCR -2,52 -1,21 0,45 0,08 U373 HTS QRT-PCR 0,61 2,56 0,59 0,53
QRT-PCR -4,21 -4,1 -4,99 n.d. QRT-PCR 1,61 1,54 0,5 1,47
confirm y y n confirm y y y y
A: ALA; D: DHA; G: GLA; T: temozolomide.
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Page 5 of 8numerous samples. By using this technology and specific
Taqman probes for each analyzed miRNA we generated
raw expression data of three different glioblastoma cells
(GBM2, GBM5 and U373) in response to different
PUFA treatment. To confirm the utility of the HTS
QRT-PCR method in miRNA expression analysis six
miRNAs were selected and their relative expression
ratios were determined in response to different treat-
ments by using traditional QRT-PCR. 75% of the data
corresponded well in both methods.
Relative changes in miRNA expression could be calcu-
lated for 65 miRNAs out of 112 with the HTS QRT-
PCR method, because of the low or undetectable expres-
sion for the rest of the miRNA.
In order to differentiate specific responses to different
PUFAs, we analyzed the effects of temozolomide, which
is an oral alkylating agent that is used in the treatment of
brain tumors [23]. The therapeutic benefit of temozolo-
mide relies on its DNA methylation ability. This methyla-
tion damages the DNA and triggers the death of tumor
cells at relatively high concentrations (over 100 μM) in
culture media. We used temozolomide to identify
miRNA expression changes that are due to apoptosis and
to see whether there are differences or similarities
between the changes caused by PUFAs.
In response to PUFA and temozolomide treatment,
specific miRNA expression changes could be detected.
However, in response to temozolomide we could record,
in addition to specific miRNA changes, alterations in the
expression of numerous other miRNAs that were simi-
larly regulated regardless of the treatment. These com-
mon changes could be secondary to the induction of
apoptosis by temozolomide and not as a result of specific
mechanism of action of the molecule.
The miRNAs that showed such common changes were
mir-34, mir-25, mir-17, mir-26a, mir-29c, mir-31, mir-
200a and mir-206. However, we could detect temozolo-
mide and PUFA-treatment specific alterations in miRNA
expression. In case of temozolomide we found specific
up-regulation of mir-182, and down-regulation of mir-16
and mir-183. Mir-143 was found to be repressed and
mir-20b was induced by PUFA treatments.
It is interesting to note that different miRNAs were
affected by treatment with the same PUFA in one cell line,
but not in another, such as mir-125b, mir-197, mir-206.
Similar cell-type specificity could be observed during gen-
eral apoptosis, where all treatments (PUFAs and temozolo-
mide) resulted in induced miRNA expression of mir-132,
mir-140-3 and mir-323 in U373 cells. These differences
can be attributed to the presence of different signalling
pathways in different tumor cell lines, depsite the fact that
the three studied cell lines were glioblastoma cells.
To confirm the importance of miRNA expression reg-
ulation during apoptosis, we listed the target genes of
Table 3 Genes having roles in apoptosis as targets of the differentially expressed miRNAs in response to PUFA
treatment
MIRNA GENE Process MIRNA GENE Process MIRNA GENE Process
miR-17 APP apoptosis miR-30c IL1A apoptosis miR-143 SMNDC1 apoptosis
FASTK apoptosis DDIT4 apoptosis NGFR apoptosis
EGLN3 apoptosis SIRT1 apoptosis KRAS apoptosis
SGMS1 apoptosis TP53INP1 apoptosis COX2 apoptosis
TP53INP1 apoptosis IRS2 apoptosis BBC3 apoptosis
TNFRSF21 apoptosis ITGB3 apoptosis ITM2B apoptosis
miR-20b APP apoptosis miR-16 CADM1 apoptosis miR-22 DPF2 apoptosis
EGLN3 apoptosis BLC2 B cell proliferation SIRT1 apoptosis
E2F1 apoptosis CADM1 cell adhesion EP300 apoptosis
FASTK apoptosis PDCD4 cell aging YARS apoptosis
miR-26a DAPK1 apoptosis miR-145 RTKN apoptosis miR-200a PDCD1 apoptosis
PAK2 apoptosis PDCD4 apoptosis NLRP3 apoptosis
BAG4 apoptosis UBE22 apoptosis SGMS1 apoptosis
UBE4B apoptosis IRS1 apoptosis CTNNB1 apoptosis
TP53INP1 apoptosis RASSF5 apoptosis NDUFS1 apoptosis
miR-29c BBC3 apoptosis miR-149 BBC3 apoptosis miR-206 BDNF anti-apoptosis
SLK apoptosis PDE1B apoptosis API5 apoptosis
AHR apoptosis PHF17 apoptosis ZMAT3 apoptosis
TP53INP1 apoptosis TNFRSF19 apoptosis BAG4 apoptosis
ELMO2 apoptosis miR-25 UBE22 apoptosis miR-34 SIRT1 apoptosis
RYBP apoptosis DYRK2 apoptosis SGPP1 apoptosis
PPARD apoptosis SGPP1 apoptosis
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temozolomide treatment. We found that most of the
target genes can be functionally classified as apoptotic
genes. Moreover, when we determined the expression of
nine selected mRNA coding genes we found an inverse
correlation between miRNA and mRNA expression in
the same treated cells. The following genes were con-
firmed as regulated at the mRNA level and their expres-
sion was correlated to our miRNA expression data: irs1,
irs2, cox2, ccnd1, sirt1, tp53inp1, itgb3, k-ras and bcl2.
In conclusion, we could demonstrate that in response
to different PUFAs the expression of miRNA and the
expression of their target mRNA coding genes were dif-
ferentially altered. Most of the regulated genes could be
classified as apoptotic genes and were up-regulated by
PUFAs and temozolomide, while the same treatment
resulted in repression of corresponding miRNAs. From
these results, we conclude that PUFAs trigger apoptosis
in glioma cells by regulating miRNA and their corre-
sponding gene expressions.
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